Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 In terms of Regulation 24 (A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time and SEBI Circular No. CIR/CFD/CMDl/27/2019 dated February 08, 2019, we enclosed herewith the annual secretarial compliance report as issued by M/s. Vishwas Sharma & Associates, Practicing Company Secretary (C, P. No. 16942), for the financial year ended on March 31, 2023.
30-05-2023
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Intimation Of Placing Of The Matter Before The Board Of Directors W.R.T Identification Of Non-Compliance Of Regulation 17(1) Of SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 ('Listing Regulations') And Subsequent Action Taken By The Exchange In The Matter.

 Intimation of placing of the matter before the Board of Directors w.r.t Identification of non-compliance of regulation 17(1) of SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 ('Listing Regulations') and subsequent action taken by the exchange in the matter.
26-05-2023
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 We enclosed herewith the copies of published newspaper advertisement with respect to the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2023.
26-05-2023
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Related Party Transactions For The Half Year Ended On 31.03.2023

 Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended on 31.03.2023
25-05-2023
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Dividend Updates

 The Board of Directors at their meeting held on today i.e. 25th May, 2023 has recommended dividend of Rs. 1.50/- (i.e 15% per share) per equity share of face value of Rs. 10/- for the year ended 31.03.2023 subject to approval of Members at the ensuing Annual General Meeting of the Company.
25-05-2023
Bigul

Lincoln Pharmaceuticals Q4 net profit jumps 13.8% to 12.56 crore

 Total income rises to 116.4 crore from 104.43 crore in Q4
25-05-2023
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - FINANCIAL HIGHLIGHTS WITH RESPECT TO AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2023

 FINANCIAL HIGHLIGHTS WITH RESPECT TO AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED MARCH 31, 2023
25-05-2023
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Resignation by Whole Time director is attached herewith.
25-05-2023
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - Corporate Action-Board approves Dividend

 Recommended a Final Dividend of Rs.1.50/- (i.e 15%) per equity shares of face value Rs.10/- each. for the year ended 31.03.2023 for the approval of the members at the ensuring AGM of the Company.
25-05-2023
Bigul

LINCOLN PHARMACEUTICALS LTD. - 531633 - FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31.03.2023

 FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31.03.2023
25-05-2023
Next Page
Close

Let's Open Free Demat Account